1. Anant Ramaswamy, MD, DM, ECMO
Medical Registration Number: TN91065
Address: 64, Gulzar Apartments, Dadoji Kondev Marg, Ranibaug, Byculla, Mumbai, Maharashtra,
400027
Mobile: (0091) 98330 93802
Email: anantr13@gmail.com
DOB: 06/05/1981
MEDICAL EDUCATION
Jul 1999 – Dec 2003 : MBBS, Armed Forces Medical College,
Maharashtra University of Health Services
Jul 2007 – Jun 2010 : MD General Medicine, King George Medical College
King George Medical University
Aug 2012 – Jul 2015 : DM (Super speciality) Medical Oncology Program
Tata Memorial Centre, Mumbai
WORK EXPERIENCE
Aug 2015 – Present : Tata Memorial Centre, Mumbai
Senior Registrar, Dept. of Medical Oncology
Aug 2012 – Jul 2015 : Tata Memorial Centre, Mumbai
Resident, Dept. Of Medical Oncology
Consultants I have worked with: Dr SD Banavali (Paediatric Oncology and Head, Dept. of
Medical Oncology); Dr Sudeep Gupta (Solid Tumors, Head of Adult Medical Oncology);
Dr Hari Menon (Head ,Adult Haematology); Dr Kumar Prabhash (Solid Tumors, Head,
Unit II Solid Tumors); Dr Navin Khattry (BMT), Dr Vanita Noronha (Solid Tumors), Dr
Brijesh Arora (Paediatric Haematology), Dr Girish C (Paediatric Solid Tumors)
Tata Memorial Hospital (TMH) is a 700 bedded tertiary cancer centre which caters to
Indian patients as well as well as patients from other parts of the Indian subcontinent. As
part of my residency during this period I gained experience in planning and giving
chemotherapy for various malignancies, along with management of complications due to
chemotherapy. Besides being responsible for admissions and inpatient management of
our adult beds, I did the out-patient clinics daily which caters to solid tumours and
haematological malignancies, and had a daily attendance of about 60-70 patients. I was
also separately posted in the BMT unit of our institution at ACTREC for a period of 6
months, where I was trained in the basics of BMT, including the planning of conditioning
protocols, stem cell storage and mobilization, monitoring and treatment of complications
associated with alloPSCT and autoPSCT. As part of training, I was also sensitized to the
workings of paediatric oncology, being posted there for 2 months.

2. Anant Ramaswamy, MD, DM, ECMO
Medical Registration Number: TN91065
Aug 2010 – Feb 2012: Apollo Speciality Hospital, Chennai
Specialist Registrar, Dept. of Medical Oncology
Consultants I have worked with: Dr Jose Easow (Hemato – Oncology, BMT and Solid
tumors); Dr Shankar Srinivasan (Hemato – Oncology and Solid Tumors)
Apollo Specialty Hospital is a 250 bedded private specialty tertiary cancer Centre that is
involved in the treatment of patients from the south of India as well as referrals from other
parts of India and the Middle East. In my position as a Specialist Registrar, I learned the
basics of medical Oncology prior to joining an academic program. I was involved in
managing in- patients of my attending, weekly on calls, and treating out-patients under
the guidance of consultants. I was also attached to the BMT Unit and made conditioning
protocols for patients along with monitoring and treating complications in post BMT
patients.
Mar 2004 – Mar 2005: Safdarjung Hospital, Delhi
Intern
EXAMINATIONS (INTERNATIONAL)
1. USMLE Step 1/2CK/2 CS/3 – ECFMG Certified (2011)
2. MRCP (UK) Step 1 & Step 2. (2009, 2010), PACES scheduled April 2016
3. Passed the ESMO 2015 Exam (26.9.2015) – ECMO certified
AFFILIATIONS
Indian Society of Medical and Paediatric Oncology (ISMPO) – Member
American Society of Clinical Oncology (ASCO) – Junior Member
European Society of Medical Oncology (ESMO) – Junior Member
PUBLICATIONS
1. Total Leukocyte Counts and the requirement of dose reduction due to cytopenias as
prognostic indicators affecting response to Imatinib in Chronic Myeloid Leukemia. Indian
J of Haematology & Blood Transfusion 2011; 27: 7-13
Tripathi AK, Kumar A, Ramaswamy A.
2. Everolimus in heavily pre-treated metastatic breast cancer (MBC): is real world
experience different? – Accepted for publication in Indian Journal of Cancer
Second author.
3. Eribulin in Heavily Pre-treated Metastatic Breast Cancer: A Tertiary Care Centre
experience from India – Accepted for publication in Indian Journal of Cancer
Second author.
4. DPD mutation in Neoadjuvant chemotherapy in head and neck cancers. Myth or reality?

3. Anant Ramaswamy, MD, DM, ECMO
Medical Registration Number: TN91065
Accepted for publication in South Asian Journal of Cancer.
Fourth author
5. DPD deficiency in patients treated with capecitabine based regimens: a tertiary care
centre experience – Accepted for publication in International Journal of Gastrointestinal
Oncology
Second author
6. Pazopanib in GIST – case series from a tertiary care cancer centre – Accepted for
publication in International Journal of Gastrointestinal Oncology
First author
ABSTRACTS
1. Addition of docetaxel to standard CF regimen as neoadjuvant chemotherapy is
efficacious and safe in nasopharyngeal carcinoma - ASCO 2015 , ID 149761
2. Dihydro Pyrimidine Dehydrogenase deficiency in patients treated with capecitabine
based regimens: a retrospective tertiary care centre experience - 2016 Gastrointestinal
Cancers Symposium (January 21-23, 2016), ID – 158943
3. Nab – Paclitaxel in MBC: A tertiary Care Centre experience from India – accepted for
ISMPO 2015
4. ALK positive lung cancer: Clinical profile and outcomes in a developing country – ELCC
2016, ID 360
POSTERS
1. Presented in SIOP 2015 - Everolimus in heavily pre-treated metastatic breast cancer
(MBC): is real world experience different?
2. ICON 2015 - DPD mutation (heterozygosity) in a case of carcinoma tongue on
neoadjuvant chemotherapy
3. Entry in competitive section and selected for final - Multi Arm, Multi Stage Phase 1/2/3
open label, randomized, prospective parallel design, superiority trial – Oral Metronomic
Chemotherapy plus intravenous Maximum Tolerated Dose (MTD) based Chemotherapy
vs MTD Chemotherapy in Recurrent / metastatic Squamous cell Head and Neck
Cancers.
CLINICAL TRIALS
1. Co-Primary Investigator - Effect of structured teaching module on incidence of the
capecitabine induced hand foot syndrome in patients of colorectal cancer at tertiary
cancer care centre.” : a prospective randomised controlled study under evaluation
with Institutional Ethics Committee
2. Co-Investigator - Prospective observational cohort study of advanced Gall bladder
cancer patients to study the impact of clinical and molecular characteristics and
outcome – multicentric study, slated to begin recruitment in approximately 2 – 3
months’ time – CTRI registered, to begin recruitment

4. Anant Ramaswamy, MD, DM, ECMO
Medical Registration Number: TN91065
HOBBIES/INTERESTS
Lawn tennis, Cinema, Fiction, Philosophy